Method for treating solid tumors
JP2025516805A5Pending Publication Date: 2026-05-29I MAB BIOPHARMA US LTD +1
Patent Information
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- I MAB BIOPHARMA US LTD
- Filing Date
- 2023-05-22
- Publication Date
- 2026-05-29
AI Technical Summary
Technical Problem
Current treatments for solid tumors, particularly progressive and metastatic forms, lack effective therapeutic targets, especially for gastric and other epithelial tumor entities.
Method used
Development of bispecific antibodies targeting CLDN18.2, which are administered to patients at dosages ranging from 0.1 to 30 mg/kg body weight, in combination with antibodies targeting 4-1BB, PD-1, PD-L1, or CD3 to enhance immune activation.
Benefits of technology
The bispecific antibodies specifically bind to CLDN18.2-expressing tumor cells and activate immune cells, such as T cells, leading to enhanced cytotoxicity and potential antitumor responses, as demonstrated by clinical trials.
✦ Generated by Eureka AI based on patent content.
Smart Images
Figure 00000026_0000 
Figure 00000026_0001 
Figure 00000026_0002
Abstract
Methods for treating solid tumors are provided herein. Specifically, methods for treating solid tumors, such as advanced and / or metastatic solid tumors, using bispecific antibodies are provided.
Need to check novelty before this filing date? Find Prior Art